Comparing of Ra Pharmaceuticals Inc. (RARX) and BioSpecifics Technologies Corp. (NASDAQ:BSTC)

Ra Pharmaceuticals Inc. (NASDAQ:RARX) and BioSpecifics Technologies Corp. (NASDAQ:BSTC) compete with each other in the Biotechnology sector. We will analyze and contrast their profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Ra Pharmaceuticals Inc. 2.50M 392.12 64.94M -2.27 0.00
BioSpecifics Technologies Corp. 32.96M 15.20 20.05M 2.40 29.63

Table 1 shows the top-line revenue, earnings per share (EPS) and valuation for Ra Pharmaceuticals Inc. and BioSpecifics Technologies Corp.

Profitability

Table 2 shows us the net margins, return on equity and return on assets of both companies.

Net Margins Return on Equity Return on Assets
Ra Pharmaceuticals Inc. -2,597.60% -72.3% -64.8%
BioSpecifics Technologies Corp. 60.83% 21.8% 20.7%

Liquidity

The Current Ratio and a Quick Ratio of Ra Pharmaceuticals Inc. are 10.3 and 10.3. Competitively, BioSpecifics Technologies Corp. has 48.4 and 48.4 for Current and Quick Ratio. BioSpecifics Technologies Corp.’s better ability to pay short and long-term obligations than Ra Pharmaceuticals Inc.

Analyst Ratings

Ra Pharmaceuticals Inc. and BioSpecifics Technologies Corp. Recommendations and Ratings are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Ra Pharmaceuticals Inc. 0 0 2 3.00
BioSpecifics Technologies Corp. 0 0 1 3.00

Ra Pharmaceuticals Inc.’s upside potential is 108.15% at a $48.5 average target price. On the other hand, BioSpecifics Technologies Corp.’s potential upside is 23.60% and its average target price is $85. Based on the analysts belief we can conclude, Ra Pharmaceuticals Inc. is looking more favorable than BioSpecifics Technologies Corp.

Insider & Institutional Ownership

The shares of both Ra Pharmaceuticals Inc. and BioSpecifics Technologies Corp. are owned by institutional investors at 95.9% and 61.3% respectively. Insiders owned 0.6% of Ra Pharmaceuticals Inc. shares. Competitively, 2.5% are BioSpecifics Technologies Corp.’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Ra Pharmaceuticals Inc. 3.13% -0.63% 37.74% 83.95% 211.45% 12.09%
BioSpecifics Technologies Corp. 2.61% 9.45% 20.32% 40.89% 78.69% 17.36%

For the past year Ra Pharmaceuticals Inc. has weaker performance than BioSpecifics Technologies Corp.

Summary

On 10 of the 12 factors BioSpecifics Technologies Corp. beats Ra Pharmaceuticals Inc.

Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The companyÂ’s peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is RA101495, an injection into the tissue under the skin for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), as well as for the treatment of other debilitating complement-mediated diseases, including refractory generalized myasthenia gravis (rMG) and lupus nephritis (LP). The companyÂ’s preclinical testing products include Factor D inhibition for age-related macular degeneration and geographic atrophy, as well as for Orphan renal dense deposit and C3 glomerulonephritis; Oral C5 inhibitor for PNH, rMG, LN, and central nervous system (CNS) diseases; and C1s inhibition for autoimmune/CNS diseases. It has multi-target collaboration and license agreement with Merck & Co., Inc. Ra Pharmaceuticals, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States. The company offers injectable collagenase for the treatment of DupuytrenÂ’s contracture and PeyronieÂ’s disease under the XIAFLEX brand in Canada and Australia, as well as under XIAPEX brand name in Europe. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, and plantar fibromatosis, as well as for the treatment of human lipoma and uterine fibroids. The company is also involved in the development of other clinical indications for which collagenase injection has been tested, such as keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. It has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Lynbrook, New York.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.